3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Kidney Neoplasms
1
Kidney Diseases
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
8
Sunitinib
7
enfortumab vedotin
6
Abiraterone Acetate
6
enzalutamide
5
Nivolumab
5
Gemcitabine
5
Cisplatin
5
Carboplatin
4
avelumab
3
Prednisone
3
Ipilimumab
3
Docetaxel
3
Androgen Antagonists
3
sacituzumab govitecan
2
olaparib
2
niraparib
2
erdafitinib
2
entrectinib
2
durvalumab
2
darolutamide
2
cabozantinib
2
belzutifan
2
apalutamide
2
Pluvicto
2
Mitomycin
2
Leuprolide
2
Everolimus
2
Axitinib
2
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has announcements
×
avelumab
×
Genitourinary
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA